MTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.

ABSTRACT:

Background

mTOR pathway is known to promote cancer malignancy and influence cancer immunity but is unknown for its role in immune checkpoint inhibitors (ICI) therapy.

Methods

Using Memorial Sloan-Kettering Cancer Center dataset (MSKCC), we extracted mTOR pathway gene mutations for stepwise Cox regression in 1661 cancer patients received ICI. We associated the mutation of the gene signature resulted from the stepwise Cox regression with the 1661 patients' survival. Other 553 ICI-treated patients were collected from 6 cohorts for validation. We also performed this survival association in patients without ICI treatment from MSKCC as discovery (n = 2244) and The Cancer Genome Atlas (TCGA) as validation (n = 763). Pathway enrichment analysis were performed using transcriptome pro

SUBMITTER: Cheng L 

PROVIDER: S-EPMC9153162 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature